Alzheimer’s: Do We Have The Wonder Drug?

by Brain Health, Featured Post0 comments

Share this page:

Since Alzheimer’s Disease (AD) was discovered over a century ago, hundreds of drugs have been tried but only three approved; two of them in the last two years.  Do we finally have a cure?  

A mountain of failure including #1

AD accounts for 70% of dementia cases. That’s why, in the USA, Alzheimer’s Disease is the umbrella term, and is the focus for most drug research. There’s a mountain of research going on; the US Alzheimer’s Association alone sponsors nearly 1,000 projects in 48 countries.

Yet, after all this effort, drug candidates have seen almost 100% failure  A study of 413 clinical trials of Alzheimer’s drugs over a 10-year period found that the success rate was a tiny 0.4%. That is, 99.6% of the drugs studied in clinical trials failed.

That study was completed after the FDA approved the first Alzheimer’s Disease (AD) drug, Tacrine in 1993, which was later withdrawn due to side effects. Tacrine, it seems was definitely not the wonder drug.

#2 didn’t fare much better

alzheimers do we have wonder drug-aduhelm
Aduhelm from Eisai & Biogen

It was  a full 18 years before the FDA approved the second dementia drug, Aduhelm – made by Eisai and marketed by Biogen under generic name Aducanemab – to great fanfare.

‘This approval is a victory for people living with Alzheimer’s and their families‘ said the CEO of the Alzheimer’s Association in 2021. This drug, like its predecessor, was approved on trials using a ‘marker’, a lab measurement which mimics a natural process. With Aduhelm, the marker was ‘amyloid-beta’, a protein in the brain said to indicate cognitive decline.  

This distinction was possible due to the FDA’s Acccelerated Approval, given for drugs ‘that treat serious conditions, and fill an unmet medical need, based on a surrogate endpoint‘ (another name for a marker). Aduhelm met all these criteria, and was given wide enough approval to be prescribed for every AD sufferer in the USA.

This approval (Aduhelm) is a victory for people living with Alzheimer’s and their families.

Alzheimer’s Association 2021

In Europe, authorities were less captivated.

Less than a year later, marketing approval for Aduhelm was withdrawn. The summary said: ‘The European Medicines Agency noted that although Aduhelm reduces amyloid-beta in the brain, the link between this effect and clinical improvement had not been established.’

In other words, the drug changed something but not brain function. The agency also raised concerns about serious side effects, including brain bleeding and swelling, which occurred in 40% of patients.  

…although Aduhelm reduces amyloid-beta in the brain, the link between this effect and clinical improvement had not been established.

European Medicines Agency 2022

In 2022, Biogen made news again, more than once.

In July it wrote down the value of its Aduhelm inventory, declaring it ‘de minimis’ or functionally worthless. In other words, the drug had no future.

Two months later, Biogen and Eisai announced promising clinical trial results for their new drug ‘Leqembi’, (generic name lecanemab).

Third time lucky?

alzheimers do we have wonder drug-leqembi
Leqembi from Eisai & Biogen

Leqembi gained also FDA Accelerated Approval, in January of 2023.

Like Aduhelm, Leqembi measures amyloid beta. We’ve been told for decades that more plaque means more dementia yet, six months after granting limited approval for Leqembi, the FDA was more muted:

In its confirmation of Leqembi’s clinical benefit in June 2023, the FDA calls amyloid plaque: ‘a marker of Alzheimer’s disease that’s believed to be associated with improved outcomes.’  Even on this basis, full FDA approval will almost certainly occur in coming months.

So, what does Leqembi do? In earlier trials, the drug apparently did reduce amyloid-beta, did slow down cognitive decline and did show about half the rate of brain-swelling and brain-bleeding compared to Aduhelm. A first for an AD drug.

A reduction in the reduction

The slow down of 27%  does sound  impressive, yet the real world adds some context: Leqembi is only effective on very early-stage AD and only 1-2% of people with dementia are tested to find out. In everyone else, there would likely be little or no benefit.

By the makers’ own admission, the trial was designed to include only sufferers in the earliest stages of AD; that is, those most likely to respond. The reality for others may be quite different.

And, the 27% reduction was in the rate of slowing not the decline itself.  In other words, patients’ brains were getting worse slightly more slowly. As neuro- psychologist Karen Sullivan put it, ‘the real-world impact of this may not be noticeable to families.’

..the real-world impact of this (slowing of rate of cognitive decline) may not be noticeable to families.

Dr Karen Sullivan, Neuro- psychologist

An unexpected paradox

An odd aspect of the Leqembi trial was this: unlike all other drugs targeting amyloid plaques, Leqembi increased soluble levels of amyloid-beta. That led researchers in the US and Sweden to turn the amyloid hypothesis completely on its head, arguing that higher levels of amyloid-beta are good, not bad. 

Confused? So was I. They found that patients with amyloid plaques in their brains were no more likely to develop dementia than the general population.

That should have thrown a spanner in the works but didn’t. Others had been saying this for years, but few were listening.  

The paradox is that so many of us accrue plaques in our brains as we age, yet the plaques remain the center of our attention …’

Dr Alberto Espay, University of Cincinatti

What’s it all about, Alfie?

In other words, there were many cases of AD without amyloid plaques, and many cases with them – but no dementia.

One who has been sceptical and about the plaque-dementia link is Dr Derek Lowe, a long-time observer and researcher in the field of AD. As he wrote Science in 2022: ‘Ever since the 1990s, researchers and clinicians have been spending uncountable hours (and uncountable dollars) trying to turn the amyloid hypothesis into a treatment for Alzheimer’s. Every single one of these interventions has failed in the clinic. Every last damn one. If you look for the best outcome of all, actual reversal of Alzheimer’s symptoms, you never see it.’

Bloomberg agrees, saying: ‘For Alzheimer’s patients, their families, researchers, and the pharmaceutical industry, the bigger question is whether drugs targeting amyloid have been a multibillion-dollar dead end.’

‘Ever since the 1990s, researchers and clinicians have been spending uncountable hours (and uncountable dollars) trying to turn the amyloid hypothesis into a treatment for Alzheimer’s’. Every single one of these interventions has failed in the clinic. Every last damn one.

Dr Eric Lowe, former AD researcher, in Science

That’s pretty strong stuff, you might say, and enough to take a hard look at the amyloid hypothesis?

‘A robust drug pipeline’

Maybe not. Despite the doubts about amyloid-beta and the drugs based on it, many dementia support websites are still pinning their hopes on both of them.  

Alzheimer’s Weekly talks about ‘recent progress made in the Alzheimer’s robust drug pipeline.’ That’s pretty surprising, given that two out of three approved drugs have failed, and the third one slows the rate of cognitive decline so little that loved ones may not even notice. The other drugs in the pipeline are in the same league.

The new candidate in the ‘robust drug pipeline’ appears to be Donanemab from Eli Lilly. It uses the same mechanism as Leqembi (an amyloid-beta marker) but is better at slowing cognitive decline; that is, it slows the decline by 2% more (if that makes sense) in mildly-impaired patients, the same early-stage ones. So far though, Donanemab shows more serious side effects so, if it will progress from pipeline to approval is yet to be seen.  

What about the patient?

Despite the focus of drug makers on amyloid plaque, or maybe because of it, the wonder drug for dementia may be still far off. After all this time, you might be tempted to ask: ‘are they looking in the wrong place‘.

You wouldn’t be alone; many now suggest that this is more than a possibility.

Away from the world of drug targets, there are many encouraging, independent studies into how to stop the progress of AD, or reverse it in the early stages. These studies are run by independent groups, mostly universities and the clinics associated with them.

Unlike the pursuers of dementia drugs, these studies are observing cognitive improvement in real people, not changes in surrogate markers that have little discernible effect. That’s why these studies are so exciting.

You can find out more about these studies, the causes of dementia (many of which are under your control), and what you can do to avoid, prevent, delay or even reverse AD. It’s all in my comprehensive eBook, Dementia: Keep Your Marbles.  

Dementia

DEMENTIA:
KEEP YOUR MARBLES

How you can avoid, delay, even reverse Alzheimer’s Disease

Kim Brebach

Kim Brebach

Hi, I’m Kim Brebach, boomer, information researcher, technical writer and Joiner of Dots at M&M. In my spare time, I review wines and love to cook.

Customer Reviews

Peter D
Just purchased a mixed case from Kemeny’s on your advice – and saved an amazing $119 on one order. Can’t wait to see how much I save in a year.

Customer Reviews

Brayden M
Very happy to pay this small fee for what is the best weekly wine mailer on offer. Keep up the great work.

Customer Reviews

Huon Hooke, Wine Writer & Critic
Kim is an outspoken defender of truth, justice and value-for-money in wine and I highly respect his opinions, his passion and his convictions.

Customer Reviews

Chris L 

The big surprise, as you say Kim, is there is literally no relationship between price and quality in the wine world. The $10 Azahara you recommended for our farewell party was ridiculously good.

Customer Reviews

Clive Davidson 

Lisa and I have an annual Xmas dinner for twenty of our closest friends and your BWW delivers the goods every year. Not a bad bottle ever. Keep up the great work, mate.

Customer Reviews

Warren Mason, Competition Director, Sydney International Wine Competition
Huge devotion! Weekly updates! A really useful consumer service. You deserve all the goodwill you have.

Customer Reviews

David Jackson  

I would never have found the Dandelion Vineyards Wonderland of the Eden Valley Riesling at Aldi for $15:00. I was down to the last two bottles and they had cost $20. Well done, Kim. Happy to recommend BWW to any person who wants fair, balanced ratings on good wines and where to buy them at bargain prices.
Customer Reviews

Carl Shipton

Didn’t know some of the wines, but I was blown away by the quality available for this kind of money. I’ve paid a lot more for labels I know and been hugely disappointed.

Customer Reviews

Peter Bourne, The Wine Man
Kim is a fearless advocate for truth and value  for wine consumers. Follow him and you’ll be informed and entertained, too.

Customer Reviews

Bec C 

Last year I used your Best Wines advice to pre-order 6 months’ supply of wine to be shipped to me overseas. What a treat! Thanks for the great resource, Kim!

Customer Reviews

Alan E  

Congratulations on a great and informative newsletter. It’s been a wonderful help in choosing good quality, reasonably priced wines. I never miss miss a week now.

Customer Reviews

Darryl Pratt, Wine Direct
The guys I deal with all respect your opinion and unbiased approach, as I do.

Customer Reviews

Peter Calder 

I buy wine for about a dozen families, for a company and for myself, with current cellar stock 1500 bottles. Your advice is a highly valued and reliable bench mark and, by the way, I am not a connoisseur collector but a consumer. I say drink and enjoy (in moderation of course)!

Customer Reviews

Bill Walter  

I continue  to buy and taste  on your recommendations and thoroughly enjoying the experience and to date, not one disappointment. Don’t plan to retire soon!

Customer Reviews

Phil Harris 

Congratulations, Kim. You’ve been an invaluable source of information and I have no doubt that I am drinking better wine as result. Having only lived in Australia for 5 years, you’ve really given me an appreciation of how much great wine this country produces. So much so that I now can take a bottle to dinner with friends who have many more years of wine experience than myself and even raise a few compliments on my selections. Safe to say I think you can a lot of the credit for that!

Customer Reviews

Nick Page

Been looking for years for someone who concentrates on the value end of the wine market. It’s written from the right perspective and reduces the legwork needed to find good wines. Thank you.

Customer Reviews

Doug B

You have a gift for wine description that mercifully avoids all the bullshit about the aromatic nuances of pear skins and Virginia tobacco leaf … Enjoying the prices, too.

Customer Reviews

Brodie Scanlan

You do great work and I wouldn’t miss your Weekly for quids. We’ve bought many 12 packs based on your lists and every bottle has been a hit.

Customer Reviews

Stuart McC

Since I subscribed a month or two ago, I’ve used your alerts to guide all my wine buying and they’ve all been good choices. Now I find myself looking forward to reading the mailer on Friday afternoon. 

Customer Reviews

Sarah P

A brilliant service, takes all the leg work out of choosing great wines.

Customer Reviews

Aunty Jack

I read with great interest every week all the wines you recommend.  I am a big fan of Riesling especially Leo Burings but have enjoyed your other recommendations Frogmore, Claymore and Heemskerk.  I buy all my wines through Kemenys as I like to support the independent wine suppliers.

Customer Reviews

James T

Bought some of the Hilltops Shiraz (hidden label) from Kemenys after reading your recommendation. Excellent choice. Love your mailer. Thanks.

 

Customer Reviews

Graham S

Four times my annual subscription saved in one transaction! How good is that, Kim?

Customer Reviews

Lambert D
I’ve ordered a couple of 6-packs from your great list of value wines. I have about 500 wines racked up in my cellar but continually need drink-now wines for daily consumption.  However, some of your suggestions are making me wonder whether I need to buy more racks … Thanks.

 

Customer Reviews

Kellie Grove
I impressed my husband…..I bought the last 6 bottles of 2015 Lizzie at our cellar.  I have also introduced him to your website.  He was very amused with some of your comments. He is now looking forward to your weekly email, too.  Keep up the great work. 

Customer Reviews

Tim Humphries

Thanks Kim, what a ripping mailer. I suspect my bank account will suffer, but the quality of wine will improve and my stockpile might also grow!  Thanks again.

 

Customer Reviews

Keith Hockly
Emailed Darryl from WineDirect re the shiraz special and got a call back within ten minutes to organise the sale. Friendly professional service. Glad I signed up.  Impressed so far!

Customer Reviews

David Klease
I usually avoid South American wine like the plague. However I went on a limb and trusted your advice on  Montes limited selection in today’s Friday mail out. For $10, it is very, very good.  Nice work Kim!!

Customer Reviews

Keith J
I enjoy your weekly email immensely and purchased a case of Wynns Coonawarra Cab Sauv from Winestar in a seamless transaction. I’m your latest fan.

Customer Reviews

Bill Walter
I continue  to buy and taste  on your recommendations and thoroughly enjoying the experience and to date, not one disappointment. Keep up the good work.

Customer Reviews

Adam F
I enjoy your irreverent look at the wine world and what it has to offer, whilst picking up some bargains along the way.

Customer Reviews

Nick Mac
Been looking for years for a website that concentrates on the value end of the market. It’s written from the right perspective and reduces the legwork needed to find good wines.

Customer Reviews

Doug B
You have a gift for wine description that mercifully avoids all the bullshit about the aromatic nuances of pear skins and Virginia tobacco leaf …

Customer Reviews

Peter E
Congratulations on your wonderful mailer. You save me hours by doing all the analysis, comparing and cross referencing for me. 

Customer Reviews

Brodie B
You do great work. We’ve bought many 12 packs based on your lists and every bottle has been a hit.

Customer Reviews

Jason W
Love the way you cut through the labyrinth of wine hype with succinct and pithy comments that are a pleasure to read.

Customer Reviews

Joan S
Great mailer! I love it and find it really useful when buying wine – you do all the leg work for me.

Customer Reviews

Chris B
Really enjoying your mailer. It’s independent, refreshingly honest, and doesn’t take itself too seriously. 

Customer Reviews

George Carter
Kim, you have an awesome wine mailer. I can sense the passion!  

Customer Reviews

Nigel
I’m loving your work, and have forwarded your mailer to my wine-loving friends.

Customer Reviews

Gary S
Great mailer! I’ve been taking your advice on wine selection, and I find your appraisals spot on.

Customer Reviews

Alan D
Congratulations on a great and informative service. It’s been a wonderful help in choosing good quality, reasonably priced wines.

Customer Reviews

Peter Daly
Best Wines Weekly is now my go-to place for ideas of new things to taste.

Customer Reviews

Daniel J
I really enjoy reading your mailer each week. It also gives me leads to wines I may have missed.

Customer Reviews

Gary Doherty
What a fantastic weekly alert with really useful lists. Thanks a lot.

Customer Reviews

Darshak R
You are performing a FANTASTIC service. More power to your keyboard!

Customer Reviews

Sandy T
Thank you so much for your excellent publication and recommendations. Spot on and really appreciated by all here. 

Customer Reviews

Chris A
Keep up the fantastic work and keep telling it like it is. 

Customer Reviews

Colin B
What a great idea! We’re drinking much better wine, and paying much less.

Customer Reviews

Col Wilson
Thank you for your weekly wine newsletter. BWW has become an important part of my life.  

Customer Reviews

Clive D
Great work on the mailer – provides a great service to those of us who have never really developed their expertise. We need to be saved from ourselves and our irrational way of making wine purchases. Really enjoy the price/quality ratio.

Customer Reviews

Peter N Wine Guru
I’ve been thinking about exactly this model for a number of years. Well done, Kim. Great work.

Customer Reviews

Chris B
I take my hat off to you and can’t thank you enough for your efforts and expertise. Keep up the fantastic work, Kim.

Select your currency